Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Takao Tsuduki
Institution:
Himeji Red Cross Hospital
Observed institution:
Himeji Red Cross Hospital
OpenAlex ID:
A5003272799
FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure
2020
·
Toshihiko Matsumoto
, Yusuke Kurioka
, et al.
·
Pancreas
·
18
Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
2022
·
Toshihiko Matsumoto
, Shogo Yamamura
, et al.
·
Journal of Clinical Medicine
·
14
PDF
Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses
2020
·
Toshihiko Matsumoto
, Yosuke Yamamoto
, et al.
·
BMC Cancer
·
12
PDF
Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab
2019
·
Toshihiko Matsumoto
, Takashi Oda
, et al.
·
International Cancer Conference Journal
·
10
Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab
2023
·
Toshihiko Matsumoto
, Tatsuki Ikoma
, et al.
·
Scientific Reports
·
9
PDF
Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)
2022
·
Akio Nakasya
, Yuya Hagiwara
, et al.
·
International Journal of Clinical Oncology
·
7
PDF
Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab
2025
·
Toshihiko Matsumoto
, Tatsuki Ikoma
, et al.
·
Scientific Reports
·
5
PDF
Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study
2022
·
Yuya Hagiwara
, Akio Nakasya
, et al.
·
Journal of Gastrointestinal Oncology
·
5
PDF
Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
2022
·
Toshihiko Matsumoto
, Shogo Yamamura
, et al.
·
Clinical Medicine Insights Oncology
·
4
Subgroup analyses of the effect of ramucirumab in pretreatment with immune checkpoint inhibitor in RINDBeRG: A randomized clinical trial in third- or further-line treatment of gastric cancer.
2024
·
Ryohei Kawabata
, Daisuke Sakai
, et al.
·
Journal of Clinical Oncology
·
2
Bleeding Risk During Colorectal Endoscopic Mucosal Resection With Continued Anticoagulant Therapy: A Multicenter Study
2025
·
Sayo Kobayashi
, Keita Harada
, et al.
·
Cureus
PDF
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G
2024
·
Toshihiko Matsumoto
, Yoshiyuki Yamamoto
, et al.
·
Targeted Oncology
PDF
Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab
2023
·
Toshihiko Matsumoto
, Tatsuki Ikoma
, et al.
·
Scientific Reports
PDF
Safety and efficacy of trifluridine/tipiracil in treatment of patients with advanced gastric cancer having ascites
2022
·
Toshihiko Matsumoto
, Shogo Yamamura
, et al.
·
Research Square
PDF
Safety and efficacy of trifluridine/tipiracil in treatment of patients with advanced gastric cancer having ascites
2022
·
Toshihiko Matsumoto
, Shogo Yamamura
, et al.
·
Research Square
FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure: retrospective analysis
2019
·
Toshihiko Matsumoto
, Shogo Kimura
, et al.
·
Annals of Oncology
PDF
Nivolumab for poor performance status patients : retrospective analysis
2019
·
Toshihiko Matsumoto
, Shogo Kimura
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
17
Citation count:
86
H-index:
6
I10-index:
4
Year
Topic
Type